The Platinum Healthcare LLC sells unapproved new drugs 'Sycosis' and 'Syphillinum' online for STIs, FDA warns.
What happened
FDA reviewed the company's website, https://platinumwellnesscenter.org/, in July 2026. It found 'Sycosis' and 'Syphillinum' available for purchase with labeling claims about gonorrhea and syphilis 'miasm.' FDA says the products are unapproved new drugs marketed for STIs and their symptoms.
What FDA found
The website labeling makes 'Sycosis' and 'Syphillinum' drugs because it says they are intended to treat disease.
FD&C Act section 201(g)(1), 21 U.S.C. 321(g)(1)The products are 'new drugs' because FDA does not generally recognize them as safe and effective for their labeled uses.
FD&C Act section 201(p), 21 U.S.C. 321(p)The company introduces or delivers the unapproved new drugs into interstate commerce without FDA-approved applications.
FD&C Act sections 301(d) and 505(a), 21 U.S.C. 331(d) and 355(a)
What FDA wants
FDA tells the company to promptly correct the violations and send a written response to FDAAdvisory@fda.hhs.gov within 15 business days of receipt of the letter, including steps taken, steps to prevent recurrence, and related documentation, with reference number 735147 in the subject line.
Who should pay attention
- online sellers and marketers of homeopathic drugs
- clinics and public health teams that manage STI care
- companies that make STI treatment claims on their websites
This is a summary. Read the original letter on fda.gov.